NCT06206252 Can Medical Cannabis Affect Opioid Use?
| NCT ID | NCT06206252 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Thomas Jefferson University |
| Condition | Chronic Pain |
| Study Type | OBSERVATIONAL |
| Enrollment | 110 participants |
| Start Date | 2023-09-07 |
| Primary Completion | 2025-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 110 participants in total. It began in 2023-09-07 with a primary completion date of 2025-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn how medical cannabis (MC) affects pain and the use of opioid pain medications. Participants who have chronic pain and use prescribed opioid pain medication will opt-in to using MC or not for the 3-month study. Participants who are certified in Pennsylvania will purchase specific medical cannabis products at a reduced cost from a partnering medical cannabis dispensary monthly. All participants will complete baseline, daily, and monthly assessments to observe changes across groups.
Eligibility Criteria
Inclusion Criteria: * Current diagnosis of chronic, intractable pain * Use of prescription opioids for longer than 90 days * Have a smartphone or agree to use one provided * English fluency * Medical cannabis group only: Willing to get certified by a physician to use medical cannabis in PA OR already certified but have not been using medical cannabis products regularly (daily or weekly) for longer than 30 days * Medical cannabis group only: Willing to accept a temporary restriction on medical cannabis products * Control group: Agree to continue not using cannabis for the duration of the study (3 months) Exclusion Criteria: * Under 18 years old * Being under conservatorship * Self-reported pregnant or breastfeeding * Cannabis Use Disorder * Active treatment in methadone or buprenorphine program for Opioid Use Disorder * Diabetic neuropathy or chemotherapy-induced neuropathy alone * Medical cannabis group: Cannabis use (daily/weekly) for more than 30 days * Control group: Cannabis Use
Contact & Investigator
Brooke Worster, MD
PRINCIPAL INVESTIGATOR
Thomas Jefferson University
Frequently Asked Questions
Who can join the NCT06206252 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06206252 currently recruiting?
Yes, NCT06206252 is actively recruiting participants. Contact the research team at mmjstudy@jefferson.edu for enrollment information.
Where is the NCT06206252 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT06206252 clinical trial?
NCT06206252 is sponsored by Thomas Jefferson University. The principal investigator is Brooke Worster, MD at Thomas Jefferson University. The trial plans to enroll 110 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.